Pharmacokinetics of dipeptidylpeptidase‐4 inhibitors

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Diabetes, obesity and metabolism

• Publication date

  2010-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1463-1326.2010.01212.xPMID 20590741
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Vildagliptin

  2012influential reference
• Vildagliptin

  2012cited by this paper
• Current Management Strategies for Coexisting Diabetes Mellitus and Obesity

  2012cited by this paper
• Saxagliptin

  2012cited by this paper
• Vildagliptin

  2012cited by this paper
• Sitagliptin

  2012cited by this paper
• Oral Antidiabetic Agents

  2012cited by this paper
• Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

  2010cited by this paper
• The Metabolism and Disposition of the Oral Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, in Humans

  2010cited by this paper
• Dipeptidylpeptidase-4 Inhibitors (Gliptins)

  2010cited by this paper
• Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects.

  2010cited by this paper
• Pharmacokinetics of the Dipeptidyl Peptidase 4 Inhibitor Saxagliptin in Rats, Dogs, and Monkeys and Clinical Projections

  2009cited by this paper
• Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

  2009cited by this paper
• Coadministration of Pioglitazone or Glyburide and Alogliptin: Pharmacokinetic Drug Interaction Assessment in Healthy Participants

  2009cited by this paper
• Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects

  2009cited by this paper
• Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase‐4 inhibitor in male type 2 diabetes patients

  2009cited by this paper
• Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin.

  2009cited by this paper
• Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.

  2009cited by this paper
• Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans.

  2009cited by this paper
• Vildagliptin in clinical practice: a review of literature

  2009cited by this paper
• Pharmacokinetics and Pharmacodynamics of Vildagliptin in Healthy Chinese Volunteers

  2009cited by this paper
• Inhibition of dipeptidyl peptidase 4 by BI-1356, a new drug for the treatment of beta-cell failure in type 2 diabetes.

  2009cited by this paper
• Tissue distribution of the novel DPP‐4 inhibitor BI 1356 is dominated by saturable binding to its target in rats

  2009cited by this paper
• Absorption, Metabolism, and Excretion of [14C]Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Humans

  2009cited by this paper
• Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events.

  2009cited by this paper
• Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes*

  2009cited by this paper
• Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.

  2009cited by this paper
• Pharmacokinetics of the dipeptidyl peptidase-4 inhibitor saxagliptin in subjects with renal impairment

  2009cited by this paper
• Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

  2009cited by this paper
• Concentration‐dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans

  2009cited by this paper
• Clinical pharmacology of alogliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of Type 2 diabetes

  2009cited by this paper
• Drug evaluation: Vildagliptin-metformin single-tablet combination

  2009cited by this paper
• Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus

  2009cited by this paper
• Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.

  2008cited by this paper
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of BI 1356, an Inhibitor of Dipeptidyl Peptidase 4, in Healthy Male Volunteers

  2008cited by this paper
• The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers.

  2008cited by this paper
• Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.

  2008cited by this paper
• Janumet™: a combination product suitable for use in patients with Type 2 diabetes

  2008cited by this paper
• Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.

  2008cited by this paper
• Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

  2008cited by this paper
• Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.

  2008cited by this paper
• Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency

  2008cited by this paper
• Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet in healthy volunteers

  2008cited by this paper
• Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.

  2008cited by this paper
• Dose Proportionality and the Effect of Food on Vildagliptin, a Novel Dipeptidyl Peptidase IV Inhibitor, in Healthy Volunteers

  2007cited by this paper
• Dose‐proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase‐4 inhibitor, in healthy volunteers

  2007cited by this paper
• Dipeptidyl peptidase‐IV inhibitors: a major new class of oral antidiabetic drug

  2007cited by this paper
• The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin

  2007cited by this paper
• Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase‐4 inhibitor, in healthy volunteers

  2007cited by this paper
• The Absolute Oral Bioavailability and Population-Based Pharmacokinetic Modelling of a Novel Dipeptidylpeptidase-IV Inhibitor, Vildagliptin, in Healthy Volunteers

  2007cited by this paper
• Transport of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin by Human Organic Anion Transporter 3, Organic Anion Transporting Polypeptide 4C1, and Multidrug Resistance P-glycoprotein

  2007cited by this paper
• Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.

  2007influential reference
• Metabolism And Excretion of the Dipeptidyl Peptidase 4 Inhibitor [14C]Sitagliptin in Humans

  2007influential reference
• Drug-Drug and Food-Drug Pharmacokinetic Interactions with New Insulinotropic Agents Repaglinide and Nateglinide

  2007cited by this paper
• Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.

  2006cited by this paper
• Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.

  2006cited by this paper
• Pharmacokinetics and Pharmacodynamic Effects of the Oral DPP‐4 Inhibitor Sitagliptin in Middle‐Aged Obese Subjects

  2006cited by this paper
• The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

  2006cited by this paper
• Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double‐blind, placebo‐controlled studies with single oral doses

  2005cited by this paper
• Drug Interactions of Clinical Importance with Antihyperglycaemic Agents : An Update.

  2005cited by this paper
• Type 2 diabetes: principles of pathogenesis and therapy

  2005cited by this paper
• The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes

  2003cited by this paper
• Oral Antidiabetic Agents

  1998cited by this paper
• Drug Treatment of Non-Insulin-Dependent Diabetes Mellitus in the 1990s

  1997cited by this paper
• Drug Treatment of Non-Insulin-Dependent Diabetes Mellitus in the 1990 s Achievements and Future Developments

  year unknowncited by this paper

• Preclinical Modeling and Simulation to Explore the Tissue/Plasma Exposure and Pharmacodynamic Effect of Vildagliptin in Diabetes Treatment

  2026cites this paper
• GPU-Accelerated Virtual Screening and Molecular Dynamics Simulations for Identification of Novel DPP‑4 Inhibitors

  2026cites this paper
• N-Nitroso-Vildagliptin, A New N-Nitrosamine Drug Substance Related Impurity (NDSRI) of Vildagliptin- An Antidiabetic Drug: Synthesis, Characterization and Development of Sensitive LC–MS/MS Method

  2025cites this paper
• Dipeptidyl Peptidase 4 Inhibitors: Novel Therapeutic Agents in the Management of Type II Diabetes Mellitus

  2025influential citation
• Comprehensive Review on Oral Hypoglycemic Agents in Geriatric Diabetic Patients

  2025cites this paper
• Metabolic reprogramming by endothelial ANGPTL4 depletion protects against diabetic kidney disease

  2025cites this paper
• New Onset Diabetes After Organ Transplantation: Risk Factors, Treatment, and Consequences

  2025cites this paper
• Renal Angptl4 is a key fibrogenic molecule in progressive diabetic kidney disease

  2024cites this paper
• DPP-4 inhibitors sitagliptin and PF-00734,200 mitigate dopaminergic neurodegeneration, neuroinflammation and behavioral impairment in the rat 6-OHDA model of Parkinson’s disease

  2024cites this paper
• Sitagliptin elevates plasma and CSF incretin levels following oral administration to nonhuman primates: relevance for neurodegenerative disorders

  2024cites this paper
• In situ evaluation of the impact of metformin or verapamil coadministration with vildagliptin on its regional absorption from the rabbit’s intestine

  2024cites this paper
• Immediate Impact of Switching from Dipeptidyl Peptidase 4 (DPP4) Inhibitors to Low-Dose (0.3 mg) Liraglutide on Glucose Profiles: A Retrospective Observational Study

  2024cites this paper
• Formulation Development and in-vitro Evaluation of Linagliptin Transdermal Patch Using Permeability Enhancer

  2023cites this paper
• Identification of levomenthol derivatives as potential dipeptidyl peptidase-4 inhibitors: a comparative study with gliptins

  2023cites this paper
• Comparison of Adverse Events Occurred During Administration of Dipeptidyl Peptidase-4 Inhibitor in Patients with Diabetes Using FDA Adverse Event Reporting System

  2023cites this paper
• DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature

  2023influential citation
• A Critical Account of Synthetic Approaches toward Vildagliptin, an Antidiabetic Drug

  2023cites this paper
• Pharmacokinetic, toxicological, and clinical considerations for the treatment of type 2 diabetes in patients with liver disease: a comprehensive update

  2023cites this paper
• Understanding the Pharmacological and Nanotechnological Facets of Dipeptidyl Peptidase-4 Inhibitors in Type II Diabetes Mellitus: a Paradigm in Therapeutics

  2023cites this paper
• GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer’s Disease Therapy

  2023cites this paper
• A model‐informed approach to accelerate the clinical development of cofrogliptin (HSK7653), a novel ultralong‐acting dipeptidyl peptidase‐4 inhibitor

  2023cites this paper
• Design, synthesis and evaluation of a series of novel long-acting dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes.

  2022cites this paper
• On the Verge of Precision Medicine in Diabetes

  2022cites this paper
• Efficacy and safety of DBPR108 (prusogliptin) as an add‐on to metformin therapy in patients with type 2 diabetes: A 24‐week, multi‐centre, randomized, double‐blind, placebo‐controlled, superiority, phase III clinical trial

  2022influential citation
• Identification of Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors from Miracle Berry Fruit (Synsepalum dulcificum) Extract

  2022cites this paper
• Mechanistic Study on the Effect of Renal Impairment on the Pharmacokinetics of Vildagliptin and its Carboxylic Acid Metabolite

  2022cites this paper
• Incretin-based drugs as potential therapy for neurodegenerative diseases: Current status and perspectives.

  2022cites this paper
• Asian Best Practices for Care of Diabetes in Elderly (ABCDE)

  2022cites this paper
• Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment

  2022cites this paper
• Pharmacokinetics, tissue distribution and excretion of compound 6c, a novel DPP-4 inhibitor, following intragastric administration in rats by ultra-performance liquid chromatography-tandem mass spectrometry.

  2022cites this paper
• REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (RP-HPLC) METHOD DEVELOPMENT AND VALIDATION OF SAXAGLIPTIN FROM HUMAN URINE

  2022cites this paper
• KDOQI US Commentary on the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD.

  2022cites this paper
• Role and mechanism(s) of incretin-dependent therapies for treating diabetes mellitus

  2022cites this paper
• Vesicles of yeast cell wall-sitagliptin to alleviate neuroinflammation in Alzheimer's disease.

  2022cites this paper
• Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment

  2022cites this paper
• " Type 2 Diabetes: Contemporary Challenges " Clinical Pharmacology of Antidiabetic Drugs: what can be expected of their use?

  2022cites this paper
• Management of post-transplant diabetes mellitus: an opportunity for novel therapeutics

  2021cites this paper
• Dipeptidyl Peptidase-4 Inhibitors and Diabetic Kidney Disease: A Narrative Review

  2021cites this paper
• Current Challenges and Future Perspectives of Renal Tubular Dysfunction in Diabetic Kidney Disease

  2021cites this paper
• Investigation of gene expression and genetic simultaneous control associated with erectile dysfunction and diabetes.

  2021cites this paper
• Drug–Drug Interactions in Vestibular Diseases, Clinical Problems, and Medico-Legal Implications

  2021cites this paper
• Comparison of biomarker and chromatographic analytical approaches to pharmacokinetic study of sitagliptin

  2021cites this paper
• Formulation development of linagliptin solid lipid nanoparticles for oral bioavailability enhancement: role of P-gp inhibition

  2020cites this paper
• Formulation development of linagliptin solid lipid nanoparticles for oral bioavailability enhancement: role of P-gp inhibition

  2020cites this paper
• Dipeptidyl peptidase-4 inhibitors and cardiovascular events in patients with type 2 diabetes, without cardiovascular or renal disease

  2020cites this paper
• The treament of hyperglycemia in acute ischemic stroke with incretin-based drugs.

  2020cites this paper
• Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence

  2020cites this paper
• Revisited: Therapeutic and toxic blood concentrations of more than 1100 drugs and other xenobiotics

  2020cites this paper
• A Safety Comparison of Metformin vs Sulfonylurea Initiation in Patients With Type 2 Diabetes and Chronic Kidney Disease: A Retrospective Cohort Study.

  2020cites this paper
• Efficacy and safety of DBPR108 monotherapy in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled, phase II clinical trial

  2020cites this paper
• STORIA NATURALE DELLA MALATTIA RENALE NEL DIABETE E TRATTAMENTO DELL’IPERGLICEMIA NEI PAZIENTI CON DIABETE DI TIPO 2 E RIDOTTA FUNZIONE RENALE

  2019cites this paper
• CARMELINA: An important piece of the DPP-4 inhibitor CVOT puzzle.

  2019cites this paper
• Using DPP-4 inhibitors to modulate beta cell function in type 1 diabetes and in the treatment of diabetic kidney disease

  2019cites this paper
• A Randomized Controlled Trial on the Safety and Efficacy of Exenatide Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes

  2019cites this paper
• Solubility profile of linagliptin: designing of transdermal formulation

  2019cites this paper
• Antidiabetic agents in patients with hepatic impairment

  2019cites this paper
• Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes.

  2019cites this paper
• Pharmacokinetic interaction between linagliptin and tadalafil in healthy Egyptian males using a novel LC-MS method.

  2019cites this paper
• Oleogel-S10 Phase 3 study “EASE” for epidermolysis bullosa: study design and rationale

  2019cites this paper
• Enhanced oral bioavailability of linagliptin by the influence of gallic acid and ellagic acid in male Wistar albino rats: involvement of p-glycoprotein inhibition

  2019cites this paper
• An up-to-date evaluation of alogliptin benzoate for the treatment of type 2 diabetes

  2019cites this paper
• Immunohistochemistry for Anti-diabetes Drug, Alogliptin Using a Newly Prepared Monoclonal Antibody: Its Precise Localization in Rat Small Intestine

  2019cites this paper
• Novel Preparation and Effective Delivery of Mucoadeshive Nanoparticles Containing Anti-diabetic Drug

  2019cites this paper
• Diabetes and Stroke: The Role of Glucose Regulation

  2019cites this paper
• Sitagliptin for prevention of stress hyperglycemia in patients without diabetes undergoing general surgery: A pilot randomized study.

  2018cites this paper
• Cardiovascular safety of DPP-4 inhibitors compared with sulphonylureas: Results of randomized controlled trials and observational studies.

  2018cites this paper
• Targeting incretin hormones and the ASK-1 pathway as therapeutic options in the treatment of non-alcoholic steatohepatitis

  2018cites this paper
• The DPP-4 inhibitor vildagliptin impacts the gut microbiota and prevents disruption of intestinal homeostasis induced by a Western diet in mice

  2018cites this paper
• The safety of gliptins : updated data in 2018

  2018cites this paper
• Determination of Dipeptidyl Peptidase-4 Inhibitors by Spectrophotometric and Chromatographic Methods

  2018cites this paper
• TRANSPORTADORES CELULARES DE DROGAS. EL VIAJE DE LOS ANTIDIABÉTICOS ORALES POR EL ORGANISMO

  2018cites this paper
• Dipeptidyl peptidase IV inhibitory properties of a whey protein hydrolysate : influence of 1 fractionation , stability to simulated gastrointestinal digestion and food-drug interaction 2 3

  2017cites this paper
• Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type‐2 diabetes patients

  2017cites this paper
• Emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin

  2017cites this paper
• Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes

  2017cites this paper
• Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes

  2017cites this paper
• Efficacy of Saxagliptin versus Mitiglinid in patients with type 2 diabetes and end-stage renal disease

  2017cites this paper
• Hepatic Dipeptidyl Peptidase-4 Controls Pharmacokinetics of Vildagliptin In Vivo

  2017cites this paper
• The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials

  2017cites this paper
• Cardiovascular outcome studies with incretin-based therapies: Comparison between DPP-4 inhibitors and GLP-1 receptor agonists.

  2017cites this paper
• Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Dovepress

  2017cites this paper
• Safety evaluation of trelagliptin in the treatment of Japanese type 2 diabetes mellitus patients

  2017cites this paper
• Production of a novel wheat gluten hydrolysate containing dipeptidyl peptidase-IV inhibitory tripeptides using ginger protease

  2017cites this paper
• Factors Associated with Type 2 Diabetes Mellitus Treatment Choice Across Four European Countries.

  2017cites this paper
• Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes

  2017cites this paper
• Population pharmacokinetics of carvedilol enantiomers and their metabolites in type-2 diabetes and healthy subjects

  2017cites this paper
• Non‐insulin anti‐diabetic drugs: An update on pharmacological interactions

  2017cites this paper
• Dipeptidyl Peptidase-4 Inhibitors in Chronic Kidney Disease: A Systematic Review of Randomized Clinical Trials

  2017cites this paper
• Linagliptin versus sitagliptin in patients with type 2 diabetes mellitus: a network meta-analysis of randomized clinical trials

  2017cites this paper
• Glucose‐lowering drugs

  2017cites this paper
• LC-MS/MS analysis of metformin, saxagliptin and 5-hydroxy saxagliptin in human plasma and its pharmacokinetic study with a fixed-dose formulation in healthy Indian subjects.

  2017influential citation
• Exploring the effects of DPP‐4 inhibitors on the kidney from the bench to clinical trials

  2017cites this paper
• Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes

  2017cites this paper
• Review of Cardiovascular Effects of Antidiabetic Drugs and Recent Cardiovascular Outcome Trials

  2016cites this paper
• Adamantane - A Lead Structure for Drugs in Clinical Practice.

  2016cites this paper
• Metabolic effects of dipeptyl peptidase 4 inhibitor in type 2 diabetes

  2016cites this paper
• Vildagliptin and its metabolite M20.7 induce the expression of S100A8 and S100A9 in human hepatoma HepG2 and leukemia HL-60 cells

  2016cites this paper
• Pharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populations

  2016cites this paper
• Sitagliptin use and risk of acute pancreatitis in type 2 diabetes mellitus: A population-based case-control study in Taiwan.

  2016cites this paper
• MicroRNA expression in the vildagliptin-treated two- and three-dimensional HepG2 cells.

  2016cites this paper